Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-3802 Monotherapy in Advanced Solid Tumors
NCT06770569Phase 1Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of HRS-3802 in solid tumor (advanced stage), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Adverse Events at 5 months, Dose-limiting toxicity at 28 days and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
HRS-3802
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06770569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770569.